How to Get Addyi (Flibanserin) in Nevada

Who Can Prescribe Addyi in Nevada?

Nevada law allows physicians (MDs and DOs), nurse practitioners with prescriptive authority, and physician assistants to prescribe flibanserin. The prescriber does not need to be a specialist. Any licensed provider comfortable diagnosing HSDD and completing the Addyi REMS certification can write the prescription.

REMS Certification Is Mandatory

The FDA requires every prescriber to enroll in the Addyi REMS (Risk Evaluation and Mitigation Strategy) program before writing a flibanserin prescription. This involves completing a brief knowledge assessment that confirms the prescriber understands the alcohol interaction risk, the need for bedtime-only dosing, and the contraindications with strong CYP3A4 inhibitors [1]. The REMS also requires that only certified pharmacies dispense the drug.

Finding a REMS-Certified Prescriber

Patients in Las Vegas, Reno, Henderson, and other Nevada cities can locate REMS-certified prescribers through Sprout Pharmaceuticals' provider directory or by calling the Addyi support line. HealthRX and other telehealth platforms that serve Nevada have REMS-certified clinicians on staff, which removes the need for patients to verify certification independently.

Telehealth Access to Addyi in Nevada

Nevada fully permits telehealth prescribing of Addyi. Premenopausal women in any Nevada ZIP code can consult a licensed, REMS-certified provider via video visit, receive a diagnosis of HSDD, and have their prescription sent to a certified pharmacy without an in-person office visit.

How a Telehealth Visit Works

A typical telehealth appointment for HSDD lasts 20 to 30 minutes. The clinician reviews symptoms against the DSM-5 criteria for HSDD, confirms premenopausal status, screens for contraindicated medications (especially moderate-to-strong CYP3A4 inhibitors like ketoconazole and fluconazole), and discusses the alcohol abstinence requirement. If flibanserin is appropriate, the prescription is electronically transmitted to a REMS-certified pharmacy that ships to Nevada.

Nevada Telehealth Regulations

Under NRS 629.515, Nevada recognizes telehealth encounters as equivalent to in-person visits for prescribing purposes, provided the provider holds an active Nevada license or a valid interstate compact license. The state does not impose a prior in-person visit requirement for controlled or non-controlled medications. Flibanserin is not a controlled substance, which simplifies the telehealth prescribing pathway.

What Labs and Screenings Are Needed Before Starting Addyi?

There is no FDA-mandated lab panel specifically for flibanserin initiation. The clinical evaluation focuses on confirming the HSDD diagnosis and ruling out other causes of low desire, such as hypothyroidism, depression, medication side effects, and relationship distress.

Recommended Pre-Prescribing Workup

Most clinicians order:

• Thyroid panel (TSH, free T4) to rule out hypothyroidism, a reversible cause of decreased libido
• Complete metabolic panel (CMP) to assess liver function, since flibanserin is hepatically metabolized via CYP3A4 [2]
• CBC if fatigue or anemia is suspected
• Hormonal panel (estradiol, testosterone, DHEA-S) to evaluate hormonal contributors, though HSDD is a neurotransmitter-mediated condition rather than a purely hormonal one

Why Liver Function Matters

Flibanserin is contraindicated in patients with hepatic impairment. The FDA prescribing information states that exposure increases approximately 4.5-fold in patients with moderate hepatic impairment (Child-Pugh B) [1]. A baseline CMP or hepatic function panel is a practical step to confirm eligibility.

How Long Until You Receive Addyi in Nevada?

From initial consultation to medication in hand, the typical timeline runs 5 to 10 business days. That timeline breaks down into discrete steps.

Step-by-Step Timeline

1. Telehealth or office visit (day 1): diagnosis and prescription
2. REMS pharmacy processing (days 2 to 4): the certified pharmacy verifies the REMS enrollment, processes the prescription, and confirms insurance or self-pay pricing
3. Shipping (days 3 to 7): most REMS-certified pharmacies ship via standard ground to Nevada addresses; expedited shipping is available at additional cost
4. Total: 5 to 10 business days for standard processing; as few as 3 days if the pharmacy offers overnight shipping

Patients in the Las Vegas and Reno metro areas may have access to local REMS-certified retail pharmacies that allow same-day or next-day pickup, reducing the wait to 1 to 3 days.

Insurance Coverage and Cost in Nevada

Addyi carries a cash price of approximately $400 to $500 for a 30-day supply at retail. Coverage varies widely between commercial payers, and Nevada Medicaid does not cover flibanserin.

Commercial Insurance

Some commercial insurers in Nevada cover Addyi with prior authorization. Plans that include a women's health formulary rider are more likely to cover it, though tier placement (typically tier 3 or specialty) means co-pays range from $50 to $150 per month. The Sprout Pharmaceuticals savings program can reduce out-of-pocket costs for commercially insured patients to as low as $0 for the first prescription fill, subject to eligibility.

Nevada Medicaid

Nevada Medicaid currently does not include flibanserin on its preferred drug list. Patients on Medicaid may pursue a non-formulary exception request, though approval rates for HSDD medications through state Medicaid programs remain low nationally.

Self-Pay and 503A Compounding Options

For uninsured or underinsured patients, 503A compounding pharmacies licensed in Nevada may offer compounded flibanserin at a lower price point than brand-name Addyi. Compounded flibanserin is prepared from bulk pharmaceutical-grade powder per a patient-specific prescription. Prices at 503A pharmacies typically range from $80 to $200 for a 30-day supply, depending on the pharmacy and formulation.

Nevada's Board of Pharmacy licenses 503A compounding pharmacies under NAC 639.585, and these pharmacies may ship within the state. Patients should confirm that the 503A pharmacy holds current Nevada licensure and follows USP <795> standards for non-sterile compounding.

Prior Authorization: What Documentation Is Required?

When a commercial insurer requires prior authorization for Addyi, the prescriber typically submits:

Standard PA Documentation

• Confirmed HSDD diagnosis per DSM-5 criteria, with documentation that the condition causes marked distress
• Premenopausal status confirmation
• Trial and failure or contraindication to behavioral therapy or counseling, if the payer requires step therapy
• Medication reconciliation showing no contraindicated CYP3A4 inhibitors
• Liver function results confirming no hepatic impairment

Timeline and Appeals

Initial PA decisions in Nevada typically arrive within 48 to 72 hours for commercial plans. If denied, patients and providers can file an expedited appeal. Nevada's insurance regulations under NRS 687B.386 require insurers to respond to expedited appeals within 72 hours when the standard timeline could jeopardize the patient's health.

Clinical Efficacy: What the Evidence Shows

Flibanserin was FDA-approved in August 2015 based on three Phase III randomized, double-blind, placebo-controlled trials in premenopausal women with generalized acquired HSDD. The drug works by modulating serotonin (decreasing 5-HT2A activity) and increasing dopamine and norepinephrine in the prefrontal cortex [2].

The BEGONIA Trial

In the BEGONIA trial (N=1,087), flibanserin 100 mg at bedtime produced a statistically significant increase in satisfying sexual events (SSEs) compared to placebo: a mean increase of 0.8 SSEs per month above placebo over 24 weeks [3]. The study also reported significant improvements in sexual desire scores on the Female Sexual Function Index (FSFI) desire domain, with a treatment difference of 0.3 points over placebo (P<0.01).

Pooled Efficacy Data

Across three key trials (DAISY, VIOLET, and BEGONIA), pooled analysis showed flibanserin increased the number of SSEs by approximately 0.5 to 1.0 events per month above placebo and reduced distress associated with low desire by roughly 0.4 points on the Female Sexual Distress Scale-Revised (FSDS-R) Item 13 [4]. The FDA's own review noted that "clinically meaningful" improvement was observed in about 10% more flibanserin-treated patients than placebo-treated patients [1].

Safety Profile

The most common side effects are dizziness (11.4% vs. 2.2% placebo), somnolence (11.2% vs. 3.2% placebo), and nausea (10.4% vs. 3.9% placebo) [1]. The principal safety concern is severe hypotension and syncope when flibanserin is combined with alcohol or moderate-to-strong CYP3A4 inhibitors. The REMS program exists specifically to mitigate this risk. As Dr. Sheryl Kingsberg, a leading HSDD researcher and past president of the International Society for the Study of Women's Sexual Health, has stated: "HSDD is a real medical condition with neurobiological underpinnings, and flibanserin addresses a genuine unmet need for premenopausal women."

Transferring an Addyi Prescription to Nevada

Patients relocating to Nevada or visiting long-term can transfer an existing flibanserin prescription from another state, but the process involves specific requirements.

How to Transfer

1. The receiving Nevada pharmacy must be REMS-certified for Addyi dispensing
2. The transferring pharmacy contacts the Nevada pharmacy and transmits the prescription record
3. The new pharmacy verifies the prescriber's REMS enrollment status
4. If the original prescriber is not licensed in Nevada, a new prescription from a Nevada-licensed provider is required

For patients moving from states where they received flibanserin via telehealth, the simplest path is to schedule a follow-up with a telehealth provider who holds a Nevada license. This creates a new in-state prescription and avoids transfer complications.

503A Compounding Pharmacies in Nevada

Nevada licenses compounding pharmacies under its Board of Pharmacy regulations. A 503A pharmacy compounds medications pursuant to individual patient prescriptions, as distinct from 503B outsourcing facilities that produce larger batches without patient-specific prescriptions.

What to Verify Before Using a 503A Pharmacy

• Active Nevada Board of Pharmacy license: searchable through the Nevada State Board of Pharmacy license lookup
• USP <795> compliance: the pharmacy should follow current United States Pharmacopeia standards for non-sterile compounding
• Source verification: the pharmacy should use FDA-registered bulk drug substance suppliers
• Shipping capability: confirm the pharmacy ships within Nevada and to your specific address; some 503A pharmacies only dispense locally

Compounded flibanserin is not subject to the REMS program (which applies only to the branded Addyi product), but the prescriber must still confirm the diagnosis of HSDD and the absence of contraindications before writing the prescription.

Alcohol and Drug Interaction Counseling

The single most important patient safety point with flibanserin is the alcohol interaction. The FDA label carries a boxed warning about severe hypotension and syncope when flibanserin is taken with alcohol [1]. Patients must abstain from alcohol for at least 2 hours before taking flibanserin at bedtime and should not consume alcohol until at least the morning after dosing.

CYP3A4 Interactions

Flibanserin is contraindicated with:

• Strong CYP3A4 inhibitors: ketoconazole, itraconazole, posaconazole, clarithromycin, telithromycin, nefazodone, and certain HIV protease inhibitors
• Moderate CYP3A4 inhibitors: fluconazole, erythromycin, ciprofloxacin, diltiazem, verapamil, and grapefruit juice (more than one glass daily)

According to the FDA prescribing information, concomitant use of flibanserin with a moderate CYP3A4 inhibitor increases flibanserin AUC by approximately 2-fold, while a strong CYP3A4 inhibitor increases AUC by approximately 4.5-fold [1]. Prescribers in Nevada should perform a thorough medication reconciliation at each visit.

Setting Realistic Expectations

Flibanserin is not a rapid-onset medication. Clinical trials demonstrated that treatment effects on sexual desire and SSEs typically emerge after 4 to 8 weeks of nightly dosing [3]. The FDA label recommends discontinuing flibanserin after 8 weeks if the patient does not report improvement in symptoms.

Dr. James Simon, a clinical professor of OB/GYN at George Washington University and principal investigator in flibanserin trials, has noted: "Patients need to understand that flibanserin works on brain chemistry gradually. It is not an event-driven medication like sildenafil. Consistent nightly use for at least 4 weeks is necessary before assessing efficacy."

Patients should also know that flibanserin treats only acquired, generalized HSDD in premenopausal women. It is not approved for postmenopausal HSDD, situational low desire, or male sexual dysfunction.